In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan ...

Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active ...